2025年世界被忽视的热带病日
在2025年世界被忽视的热带病日，世界卫生组织（世卫组织）呼吁包括领导人和社区在内的所有人团结起来，采取行动，通过大胆、可持续的投资，消除被忽视的热带病，使世界上最脆弱社区的约15亿人摆脱疾病和贫穷的恶性循环。
Related Articles
What Is Acupressure? How It Works
While acupressure doesn’t use acupuncture, it focuses on similar pressure points to relieve certain symptoms. Here’s how to find the pressure points and use them…
The new normal for hospital capacity
“Learn how hospital capacity challenges have evolved since 2020, with flu, COVID-19, and RSV creating a “tripledemic” and causing significant operational challe
Apple Intelligence so far: did Apple oversell it?
There’s still much more to come with Apple Intelligence.
CVS Health’s new app aims to be a one-stop shop for customers, members
CVS Health is rolling out a new customer app that aims to make it simpler and more convenient for users to manage health benefits, pharmacy…
Opioid Overdose Epidemic Podcast Series on AMA Ed Hub
Listen to expert discussions and insights to help PCPs and other HCPs address the epidemic of opioid overdoses. Learn about treatment options for pain management,…
Takeaways from RFK Jr.’s first day before Congress
This week in health care policy and politics news: The first RFK Jr. Senate hearings, and RFK Jr.’s private emails show vaccine criticism.
Trump administration’s halt of CDC’s weekly scientific report stalls bird flu studies | CNN
The Trump administration has intervened in the release of important studies on the bird flu, as an outbreak escalates across the United States.
Inside Pluton — Microsoft’s security processor that’s coming to a PC near you soon
Microsoft first announced its Pluton security processor as far back as 2020 and more recently has said it will be enabled by default on all…
NCPA: Independent pharmacies weigh stocking drugs under Medicare price negotiation
The National Community Pharmacists Association (NPCA) is warning the feds that independent pharmacists are likely to face significant financial hardship due to Medicare drug price…
FDA Approves Meloxicam and Rizatriptan (Symbravo) for Acute Migraine With or Without Aura
Axsome Therapeutics announced that the FDA approved the NDA for AXS-07 to treat acute migraine with or without aura on January 30, 2025.
